Strong Growth and Future Prospects: Eli Lilly Continues to Shine

With a market cap of $799.5 billion, Eli Lilly and Company (LLY), based in Indianapolis, Indiana, stands as a leading player in the global pharmaceutical industry. The company is well-known for groundbreaking medications such as Prozac for depression, Humalog for diabetes, and Mounjaro for type 2 diabetes.

LLY Outperforms Market Standards

Over the past year, Eli Lilly’s shares have outshone the broader market. LLY has increased 24.6% in value during this period, exceeding the S&P 500 Index’s ($SPX) 22.6% gain. Furthermore, LLY stock is up by 13.8% year-to-date, while the SPX has seen a modest increase of 3.3%.

In addition, Eli Lilly has surpassed the Health Care Select Sector SPDR Fund’s (XLV) 2.8% rise over the same 52 weeks.

Positive Q4 Earnings Boost Investor Confidence

On February 6, Eli Lilly’s stock jumped 3.3% following a robust Q4 earnings report. The company reported a year-over-year revenue increase of 45%, reaching $13.5 billion. This growth was largely fueled by strong sales of its diabetes and obesity treatments, Mounjaro and Zepbound. Adjusted earnings per share (EPS) more than doubled to $5.32, exceeding analysts’ forecasts. Looking ahead, Eli Lilly remains optimistic, projecting 2025 sales between $58 billion and $61 billion, which has further strengthened investor sentiment.

For the fiscal year 2024, which concluded in December, LLY posted an adjusted EPS of 12.99. The company has exhibited a mixed earnings surprise history, beating consensus estimates in three out of the last four quarters but missing them once.

Analyst Ratings Show Strong Support

Among the 24 analysts covering Eli Lilly, there is a consensus rating of “Strong Buy.” This rating reflects 19 “Strong Buy” recommendations, one “Moderate Buy,” and four “Holds.”

However, this rating is slightly less optimistic than three months ago, when there were 20 “Strong Buy” ratings.

Future Growth Prospects with CagriSema

On February 6, Bernstein reaffirmed its “Outperform” rating on Eli Lilly with a price target of $1,100. This reflects positive expectations regarding the company’s upcoming weight loss treatment, CagriSema.

Currently, LLY trades below the average price target of $988.61. The highest target from analysts is $1,190, indicating a potential upside of 37.1% from current levels.

On the date of publication, Sohini Mondal did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are intended for informational purposes only. For further details, please view the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.